Purpose Despite the intention of international psoriasis treatment guidelines to cover all patients globally, disparities persist in the availability and accessibility of adequate therapy in many countries. The Global Healthcare Study on Psoriasis (GHSP) aims to study patient characteristics, disease impact, treatment accessibility and healthcare systems worldwide.
This study provides a description and data analysis of 22 countries. Participants The GHSP cohort was initiated in 2020, and the number of recruiting centres has gradually grown.
Participants are recruited by dermatologists at reference centres worldwide. Data are collected using a standardised assessment questionnaire comprising 88 items, administered by trained experts.
Findings to date By 26 October 2024, cross-sectional data had been collected from 3950 psoriasis patients at 130 reference centres in 22 countries on six continents. The majority (55.7%) of patients were male, and the median (IQR) body mass index was 26.5 (23.7 - 30.1) kg/m 2 .
The median (IQR) Psoriasis Area and Severity Index was 5.0 (2.0 - 11.4), and median (IQR) Dermatology Life Quality Index was 7.0 (2.0 - 14.0).
BMJ Open published a clinical update in Research Highlights on 19 May 2026.
The item focuses on Global Healthcare Study on Psoriasis (GHSP): cohort profile and first findings.
Review the original article for the full source wording and details.